An Autoantibody Test (AABT) to Aid in Early Detection of Lung Cancer in High-Risk Patients is Likely to be Cost-Effective

Peter Boyle¹, Derek Weycker², Anne Khuu², James R. Jett³, Frank C. Detterbeck⁴, Timothy C. Kennedy⁵, Daniel L. Miller⁶, Herbert Fritsche⁷, William C. Wood⁶, Geoffrey Hamilton-Fairley⁸, John F. R. Robertson⁹, John Edelsberg² ¹International Prevention Research Institute (iPRI), Lyon, France; ²Policy Analysis Inc. (PAI), Brookline, MA; ³Mayo Clinic, Rochester, MN; ⁴Yale University, New Haven, CT; ⁵University of Colorado Cancer, Denver, CO; ⁶Emory University, Atlanta, GA: ⁷MD Anderson Cancer Center, Houston, TX: ⁸Oncimmune Ltd., Nottingham, England: ⁹The University of Nottingham, Nottingham, England

BACKGROUND

- Lung cancer (LC) is most common cause of cancer death in US, in part because it typically is not diagnosed until advanced stages
- Trials suggest screening with computed tomography (CT) may yield favorable shift in LC stage at diagnosis, although a survival benefit has not been convincingly shown
- AABT—EarlyCDT-Lung (Oncimmune Ltd)—to aid in LC detection recently developed:
- AABT comprises panel of 6 tumor-related antigens found to be present in LC several years before any tumor can be detected
- Thus, although less sensitive than CT, AABT can detect smaller, less-advanced cancers; it also has greater specificity than CT
- Patients with AABT+ (and CT+) are more likely to have LC and thus may be more aggressively evaluated and treated, which may yield tangible (eg, survival) benefits

STUDY OBJECTIVE

 To estimate cost-effectiveness of screening high-risk patients for LC with AABT, using techniques of decision-analytic modeling

STUDY METHODS

- Model denicts clinical and economic consequences of alternative strategies for IC screening in cohort of 100,000 previously unscreened high-risk patients
- Model considers a single "prevalence-round" screening exam

Screening strategies include:

- AABT followed by CT if positive (AABT→CT)
- AABT plus CT (AABT+CT) • CT alone
- No Screening

Patients assumed to be 60 years of age and at high-risk of having previously undetected LC due to current or former smoking:

• NSCLC—aggressive and indolent types—and SCLC considered

Patients classified into one of four groups-true-positive, true-negative, falsepositive, false-negative-based on LC+ vs LC- and screening+ vs screening-

True-positives undergo further diagnostic evaluation followed by LC treatment:

- · Diagnostic tests employed, and their scheduling, depend on whether AABT and/or CT are positive, and nodule size
- Detection of aggressive NSCLC/SCLC by CT screening yields earlier stage and smaller tumor (NSCLC stage 1), which confer survival benefits (vs no screening):
- LC detected with AABT assumed, on average, to be smaller and less advanced, which results in stage, size, and survival benefits
- Detection of indolent NSCLC by screening ("overdiagnosis bias") generates additional costs but confers no survival benefit

Model Description (Cont.)

- True-negatives undergo no further diagnostic evaluation
- False-positives undergo additional evaluation that ultimately rules out diagnosis False-negatives with aggressive NSCLC/SCLC are correctly diagnosed, on average, 12
- months following screening and subsequently undergo LC treatment:
- · Cancer assumed to have same size/stage as that detected in clinical practice, and thus to be more advanced than that for true-positives
- Most patients with false-negative indolent NSCLC are never diagnosed
- · Costs include: initial screening (all patients); follow-up diagnostic evaluation (truepositives and false-positives); LC treatment (true-positives and false-negatives) Study perspective: healthcare system
- Future benefits and costs (2008US\$) discounted at 3% per year

Model Estimation

- LC prevalence estimated assuming a three-year "look-forward period":
- · AABT+ could result from tumor detectable by CT at time of screening or from one so small it would not be detectable by CT for up to three years
- CT sensitivity/specificity calculated from "prevalence-screen" perspective based on results of Mayo Clinic study¹⁻³: for AABT, estimates based on published data^{4,5}

	Value		
Model Parameter	NSCLC	SCLC	Reference
Disease Characteristics			
Prevalence of Lung Cancer, %	3.20%	0.56%	1-3, 6, 7
Type of Lung Cancer, %	85%	15%	7
Screening Test Characteristics			
ст			1-3
Sensitivity	47%	47%	
Specificity	49%	49%	
AABT			4,5
Sensitivity	40%	40%	
Specificity	90%	90%	
Stage Shift vs No Screening, %			
ст	50%	25%	8 (NSCLC), Expert Opinion (SCLC
AABT→CT	80%	40%	Expert Opinion
AABT+CT	67.6%	34.3%	Derived
Size Shift (Stage 1) vs No Screening, mm			
ст	16.0		2
AABT→CT	18.0		Expert Opinion
AABT+CT	17.2		Derived
Overdiagnosis Bias, %	27%		9
Costs			
Initial Screen			
ст	\$301	\$301	10
AABT	\$300	\$300	Assumed
LC Treatment			11
Initial Year (Stage 1 - 4)	\$35,871 - \$50,346	\$50,346	
Continuing Years (Annual)	\$4,576	\$4,576	
Last Year of Life (Stage 1 - 4)	\$46.295 - \$78.623	\$78.623	

Analyses

- Cost-effectiveness calculated as ratio of difference in expected costs to difference in expected quality-adjusted life-years (QALYs) between:
- AABT→CT vs No Screening and CT alone, respectively
- AABT+CT vs No Screening and CT alone, respectively
- CT vs No Screening

RESULTS

• Of 2,901 cases of aggressive NSCLC/SCLC, 1,161 (true-positives) would be detected with AABT→CT. 1.979 with AABT+CT. and 1.363 with CT alone: false-positives would total 9.623 (AABT→CT), 53.794 (AABT+CT), and 49.079 (CT alone)

Table 2. Classification from screening for lung cancer in a hypothetical population of 100,000 current/former smokers


currenty former smoker				
	No Screening	СТ	AABT→CT	AABT+CT
True Negatives	96,234	47,155	86,611	42,440
False Positives		49,079	9,623	53,794
True Positives		1,770	1,507	2,569
NSCLC		1,505	1,281	2,184
Aggressive		1,098	935	1,594
Indolent		407	346	590
SCLC		265	226	385
False Negatives	3,766	1,996	2,259	1,197
NSCLC	3,202	1,697	1,921	1,018
Aggressive	2,337	1,239	1,402	743
Indolent	865	458	519	275
Detected	123	0	0	0
Undetected	742	458	519	275
SCLC	564	299	338	179

Compared with no screening, screening would increase costs by \$497 (AABT→CT), \$1242 (AABT+CT), and \$802 (CT alone) per patient, and yield an additional 0.04 (AABT→CT), 0.05 (AABT+CT), and 0.03 (CT alone) QALYs per patient

Table 3. Outcomes from screening for lung cancer in a hypothetical population of 100,000	
current/former smokers*	

1,510 1,306 \$311,162	1,511 1,307 \$280,676	1,513 1,308 \$355,165
\$311,162	\$280,676	\$355,165
\$30,051	\$33,345	\$60,051
\$51,227	\$23,018	\$61,011
\$229,883	\$224,313	\$234,103
	\$51,227	\$51,227 \$23,018

RESULTS (CONT.)



Sensitivity Analyses

	AABT	AABT->CT vs		CT vs
	No Screen	ст	No Screen	ст
Base-case	\$13,830	Dominant	\$24,473	\$17,592
Prevalence				
Age 50 (1.07%)	\$32,329	Dominant	\$55,775	\$39,848
Age 70 (7.88%)	\$13,902	Dominant	\$22,604	\$17,399
Cost of AABT screening				
\$0	\$5,487	Dominant	\$18,563	\$5,598
\$100	\$8,268	Dominant	\$20,533	\$9,596
\$200	\$11,049	Dominant	\$22,503	\$13,594
\$500	\$19,392	Dominant	\$28,413	\$25,588
Sensitivity - AABT				
20%	\$24,413	\$48,272 (CT)	\$28,331	\$24,069
30%	\$17,432	Dominant	\$26,230	\$20,203
60%	\$10,182	Dominant	\$21,685	\$14,271
Specificity - AABT				
80%	\$18,722	Dominant	\$26,496	\$21,697
95%	\$11,384	Dominant	\$23,462	\$15,540
Stage Shift - AABT-→CT				
NSCLC 65%, SCLC 40%	\$17,706			
NSCLC 50%, SCLC 40%	\$23,718			
NSCLC 25%, SCLC 40%	\$47,254			
NSCLC 80%, SCLC 0%	\$12,990			
Stage Shift - AABT-→CT vs CT				
NSCLC 65% vs 50%, SCLC 40% vs 25%		Dominant		
NSCLC 50% vs 50%, SCLC 40% vs 25%		\$95,654 (CT)		
NSCLC 25% vs 25%, SCLC 40% vs 25%		\$273,049 (CT)		
NSCLC 80% vs 50%, SCLC 0% vs 0%		Dominant		
Stage Shift - AABT+CT				
NSCLC 50%, SCLC 34.3%			\$34,042	
NSCLC 25%, SCLC 34.3%			\$68,321	
Stage Shift - AABT+CT vs CT				
NSCLC 50% vs 50%, SCLC 34.3% vs 25%				\$40,119
NSCLC 25% vs 25%, SCLC 34.3% vs 25%				\$78,472

CONCLUSION AND CLINICAL IMPLICATION

- Screening high-risk patients for LC using AABT, in conjunction with CT, is likely to be cost-effective by current standards in comparison with CT screening or no screening
- Use of AABT in early detection of lung cancer is supported by clinical as well as economic evidence

REFERENCES

- Fry, Cancer 1996;77:1947-55
 Mahadevia, JAMA 2003;289:313-22
 Lindell, Radiology 2007;242:555-62
 RBRVS 2008; Chicago, III: American Medical Association
 Yabroff, J Natl Cancer Inst 2008;100:630-41 Swensen, Am J Respir Crit Care Med 2002;165:508-13
- Swensen, Radiology 2003;226:756-61
 Swensen, Radiology 2005;235:259-65
 Boyle, JCO 2010;in press Murray, Ann Oncol 2010;doi:10.1093/annonc/mdp60 SEER Cancer Statistics Review 1975-2006.NCI websit